 | Review waiting, please be patient.
This may take 3 months or more, since drafts are reviewed in no specific order. There are 5,124 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
Comment: In accordance with the Wikimedia Foundation's Terms of Use, I disclose that I have been paid by my employer for my contributions to this article. JamiTaylor (talk) 00:24, 9 July 2026 (UTC)
Vivani Medical is a clinical-stage biopharmaceutical company based in Alameda, California.[1][2] The company develops long-acting subdermal drug implant candidates, including GLP-1 receptor agonist implant programs, using a platform it calls NanoPortal.[3][4] Vivani Medical trades on the Nasdaq stock exchange under the ticker symbol VANI.[5][6]
History
editVivani was formed in 2022 through a reverse merger of Second Sight Medical Products and Nano Precision Medical.[6] According to BioWorld, Second Sight shareholders held about 23 percent of the combined company, which adopted the name Vivani Medical and shifted its focus toward miniaturized subdermal drug implants.[6] Second Sight had previously developed neurostimulation technology, including the Orion visual cortical prosthesis program.[7]
In July 2026, Vivani announced a definitive agreement to sell its Cortigent subsidiary to Nasdaq-listed ClearOne, Inc. If completed, ClearOne would be renamed Cortigent Holdings, Inc., and the combined company would operate as Cortigent.[8]
Technology and pipeline
editThe company describes NanoPortal as a subdermal implant platform for long-acting drug delivery.[2] The implant candidates are investigational.[4]
NPM-139 is a semaglutide implant candidate under development for chronic weight management.[3][4] Vivani identifies NPM-139 as its lead drug implant candidate.[9]
Novo Nordisk evaluation agreement
editIn July 2026, Vivani announced that Novo Nordisk would conduct a non-exclusive internal evaluation of NPM-139.[3] The company said the agreement did not include exclusivity provisions.[3]
References
edit- ↑ "Contact Us". Vivani Medical. Retrieved 2026-07-07.
- 1 2 "Our Company". Vivani Medical. Retrieved 2026-07-07.
- 1 2 3 4 Adams, Ben (2026-07-07). "Novo Nordisk pens long-acting GLP-1 implant tech deal with Vivani Medical". Fierce Biotech. Retrieved 2026-07-07.
- 1 2 3 Floersh, Helen (2024-03-01). "Vivani's exenatide implant stimulates weight loss as well as Wegovy in mice". Fierce Biotech. Retrieved 2026-07-07.
- ↑ "Vivani Announces Trading under New Ticker Symbol (Nasdaq: VANI)" (Press release). Vivani Medical.
- 1 2 3 Boyle, Annette (2022-08-30). "Second Sight saga closes another chapter with Nano Precision merger". BioWorld. Retrieved 2026-07-07.
- ↑ Taylor, Nick Paul (2025-03-13). "Vivani to spin off neurostimulation business". MedTech Dive. Retrieved 2026-07-07.
- ↑ Whooley, Sean (2026-07-02). "Vivani to sell neurotech subsidiary Cortigent to ClearOne". MassDevice. Retrieved 2026-07-07.
- ↑ Vivani Medical, Inc. (2026-03-26). Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (PDF) (Report). U.S. Securities and Exchange Commission. Retrieved 2026-07-07.